Teladoc Health’s acquisition of Livongo Health requires a leap of faith. One lossmaking virtual health group is buying another for $18.5bn, including debt. The deal is predicated on the assumption that the explosive growth seen in telemedicine will continue after the coronavirus pandemic blows over. It’s a hefty bet. An initial 20 per cent slump in Teladoc’s share price on Wednesday shows investors need convincing.
Teladoc Health收购Livongo Health需要非同一般的极大信心。一家亏损的虚拟健康集团正以185亿美元收购另一家亏损的虚拟健康集团，其中包括债务。这笔交易基于这样的假设，即在新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）大流行结束后，远程医疗领域的爆炸性增长仍将继续。这是一场豪赌。周三，Teladoc股价开盘下跌20%，表明投资者还需要说服。
您已阅读21%（606字），剩余79%（2298字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。